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Early results from epidemiologic studies did not demonstrate conclusively that mammographic screening significantly reduces breast cancer mortality in younger women. More recent data obtained over longer periods of follow-up of screened women demonstrate that rnamrnographic screening of 40-to 49-year-old women can decrease mortality from breast cancer [1 , 2] . However, the incidence of breast cancer is much lower in women who are 40-49 years old than in women who are more than 50 years old. Consequently, many more young women must be screened to detect a single case of breast cancer. (SEER) study, were 76% and 74% for women younger and older than 50 years, respectively.
A recent two-county study in Sweden examined the higher occurrence of interval breast cancers in women younger than 50 years old [2] . The findings of this study may partially explain the lower reductions in mortality observed in screened women who are 40-49 years old [2] . In this study, women were screened with single-view mammography;
women under age 50 were screened at 24-month intervals, and women who were 50 years old or older were screened at 33-month intervals. Survival rates for screened women with interval cancers detected by physical examination were similar to those in nonscreened women. The epidemiologic evidence reported by Eddy et al. [3] , and strengthened by the recent analyses described here, demonstrates that mammographic screening can reduce breast cancer mortality in women who are 40-49 years old. However, whether these data are sufficient to recommend mammographic screening of all asymptomatic women in this age group is controversial. Uncertainties include which screening interval is preferable in younger women and whether the fiscal resources required for such a program might be better used in other public health programs. One way to help resolve the controversy would be a dedicated effort by radiologists to reduce the charge for mammographic screening by developing more efficient and cost-effective ways to offer screening services. Also, objective discussion in medical meetings and publicforums of all the issues surrounding the mammographic screening of younger women would facilitate rational publichealth decisions regarding the screening of younger women.
